Study of Icrucumab (IMC-18F1) or Ramucirumab Drug Product (DP) in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients
Clinical trial NCT01234402 · COMPLETED
Trial details
- NCT number
- NCT01234402
- Sponsor
- Eli Lilly and Company
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2011-03-01
- Primary completion
- 2013-10-01
- Enrollment
- 153
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.